Chafic Karam, MD
Neurology
Accepting new patients
Sees patients age 18 and up
Penn Neuroscience Center - Neurology
Penn Medicine Provider

About me

  • Chief, Neuromuscular Division
  • Professor of Clinical Neurology

Education and training

  • Medical School: Saint Joseph's University
  • Residency: Mount Sinai Hospital
  • Residency: Mass General Brigham Healthcare Center - Chestnut Hill
  • Residency: Mayo Clinic

What my patients think about me

Average Rating

190 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

December 2025
dr. karam was very polite, informative, and listened well.
September 2025
have already recommended them
September 2025
great dr
September 2025
i would highly recommend dr. karam.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Karam is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Karam C. Clinical Utility of Serum Neurofilament Light Chain in Peripheral Neuropathy. , Muscle Nerve. : 2026,73(1):86-92.


Vu T, Durmus H, Rivner M, Shroff S, Ragole T, Myers B, Pasnoor M, Small G, Karam C, Vullaganti M, Peltier A, Sahagian G, Feinberg MH, Slanksy A, Barnett-Tapia C, Siddiqi Z, Gwathmey K, Badruddoja MA, Kamboh H, Ruggerie RN, Fedak RR, Stewart CA, Kurtoglu M, Kalayoglu M, Singer M, Jewell CM, Miljkovic MD, Dimachkie M, Mozaffar T, Howard JF Jr; MG-001 Study Team. BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial , Nat Med. : 2026


Fedak RR, Ruggerie RN, Shan Y, Curvino EJ, de Sousa JF, Daniel S, Ngo-Casi M, Kamboh H, Vu T, Durmuş H, Mozaffar T, Howard JF Jr, English EP, Benson A, Duvernay MT, Singer MS, Kalayoglu MV, Brunn C, Bodansky A, Anderson MS, DeRisi JL, Garcia ST, Yu DJL, Zorn KC, Kurtoglu M, Miljković MD, Stewart CA, Jewell CM; MG-001 Study Team. BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial , Nat Med: 2026


Singh A, Wyatt J, Théaudin M, Karam C, Kasper D, Streubel B, Frascello K, Bondue A. Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis , Journal of Clinical Medicine.: 2025


Khandelwal N, Sanchirico M, Ajibade A, Munshi K, Vu M, Engel-Nitz N, Steiger C, Anderson AJ, Karam C. Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients with Multifocal Motor Neuropathy: A US Claims Database Cohort Study , J Health Econ Outcomes Res. 2025 Jun 26;12(1):261-268. : 2025


Hsu RT, Wilson J, Karam C. Amyloid Spikes on Optical Coherence Tomography Demonstrating Ocular Involvement in ATTRv Amyloidosis , Neurology. : 2025


Bril V, Drużdż A, Grosskreutz J, Habib AA, Kaminski HJ, Mantegazza R, Sacconi S, Utsugisawa K, Vu T, Boehnlein M, Gayfieva M, Greve B, Woltering F, Vissing J; MG0004 study investigators. Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. , J Neurol.: 2025


Morganroth J, Karam C. Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments , Neurol Clin Pract. : 2025


Rebello, S., Hsu, K., Nativi-Nicolau, J., Karam, C., Grogan, M., Lousada, I., & Maurer, M. S. Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey. , Amyloid, 1–10: 2025


Karam C, Pasnoor M, Barohn RJ, Dimachkie MM. Acquired and Genetic Amyloid Neuropathies , Neurol Clin. 2025 Nov;43(4):837-849. : 2025


View all publications